Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences
02 Mars 2021 - 08:00AM
Business Wire
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that
designs and develops virus-based immunotherapeutics against cancer,
today announces that members of Transgene’s management and
scientific team have been invited to participate at upcoming
(virtual) scientific conferences:
- ESMO Targeted Anticancer Therapies Congress 2021 which
will take place March 2-4: Éric Quéméneur, Executive Vice President
and Chief Scientific Officer (CSO), will be speaking in the session
'Where next with Oncolytics' about Antibody armed oncolytic
viruses (ID 42) Date & Time: March 3rd at 4.20pm (CET)
- Royal Society Meeting on 'Immuno-oncology: How to get the
immune system to beat cancer' which will take place March
24-25: This Royal Society meeting will explore immuno-oncology
therapies - both current and recent technologies. Eric Quéméneur
will participate in the immuno-oncology breakthroughs
session. Date & Time: March 24th at 3.50pm (GMT)
- 4th Annual European Neoantigen Summit which will take
place April 20-22: Kaidre Bendjama, Project Leader, Personalized
Cancer Vaccines, will be speaking about TG4050: Viral
immunotherapy meets AI technology Date & Time: April 22nd
at 1pm (CET)
About Transgene Transgene (Euronext: TNG) is a
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic
vaccines (TG4001 for the treatment of HPV-positive cancers, and
TG4050, the first individualized therapeutic vaccine based on the
myvac® platform) as well as two oncolytic viruses (TG6002 for the
treatment of solid tumors, and BT-001, the first oncolytic virus
based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters
the field of precision medicine with a novel immunotherapy that is
fully tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building
on its viral vector engineering expertise to design a new
generation of multifunctional oncolytic viruses. Transgene has an
ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at:
www.transgene.fr // Follow us on Twitter: @TransgeneSA
Disclaimer This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210301005977/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: Citigate Dewe Rogerson David Dible/Sylvie
Berrebi +44 (0)20 7638 9571
transgene@citigatedewerogerson.com
Transgene (EU:TNG)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Transgene (EU:TNG)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024